Naber KG - Search Results

1

Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies.

Johansen TE, Cek M, Naber KG, Stratchounski L, Svendsen MV, Tenke P; PEP and PEAP-study investigators; Board of the European Society of Infections in Urology. Johansen TE, et al. Among authors: naber kg. Int J Antimicrob Agents. 2006 Aug;28 Suppl 1:S91-107. doi: 10.1016/j.ijantimicag.2006.05.005. Epub 2006 Jul 7. Int J Antimicrob Agents. 2006. PMID: 16829052 Review.

2

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement.

Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, Palou Redorta J, van Cangh PJ. Bjerklund Johansen TE, et al. Among authors: naber kg. Eur Urol. 1998 Dec;34(6):457-66. doi: 10.1159/000019784. Eur Urol. 1998. PMID: 9831786 Review.

3

Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group.

Krcmery S, Naber KG. Krcmery S, et al. Among authors: naber kg. Int J Antimicrob Agents. 1999 Feb;11(2):133-8. doi: 10.1016/s0924-8579(98)00088-0. Int J Antimicrob Agents. 1999. PMID: 10221416 Clinical Trial.

4

Complicated urinary tract infections.

Melekos MD, Naber KG. Melekos MD, et al. Among authors: naber kg. Int J Antimicrob Agents. 2000 Aug;15(4):247-56. doi: 10.1016/s0924-8579(00)00168-0. Int J Antimicrob Agents. 2000. PMID: 10929873 Review.

5

Survey on antibiotic usage in the treatment of urinary tract infections.

Naber KG. Naber KG. J Antimicrob Chemother. 2000 Sep;46 Suppl 1:49-52; discussion 63-5. J Antimicrob Chemother. 2000. PMID: 11051624

6

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.

Naber KG, Hollauer K, Kirchbauer D, Witte W. Naber KG, et al. Int J Antimicrob Agents. 2000 Nov;16(3):239-43. doi: 10.1016/s0924-8579(00)00222-3. Int J Antimicrob Agents. 2000. PMID: 11091042

7

Which fluoroquinolones are suitable for the treatment of urinary tract infections?

Naber KG. Naber KG. Int J Antimicrob Agents. 2001 Apr;17(4):331-41. doi: 10.1016/s0924-8579(00)00362-9. Int J Antimicrob Agents. 2001. PMID: 11295418

8

Urinary tract infection in adults: research priorities and strategies.

Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, Naber KG, Hooton TM, Johnson J, Chambers S, Andriole V. Ronald AR, et al. Among authors: naber kg. Int J Antimicrob Agents. 2001 Apr;17(4):343-8. doi: 10.1016/s0924-8579(01)00303-x. Int J Antimicrob Agents. 2001. PMID: 11295419

9

In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections.

Onda H, Wagenlehner FM, Lehn N, Naber KG. Onda H, et al. Among authors: naber kg. Int J Antimicrob Agents. 2001 Sep;18(3):263-6. doi: 10.1016/s0924-8579(01)00374-0. Int J Antimicrob Agents. 2001. PMID: 11673040

10

Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.

Naber KG, Savov O, Salmen HC. Naber KG, et al. Int J Antimicrob Agents. 2002 Feb;19(2):95-103. doi: 10.1016/s0924-8579(01)00481-2. Int J Antimicrob Agents. 2002. PMID: 11850161 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

413 results

Search Page